Kidney hope: two-pill combo may slow damage in diabetic patients
NCT ID NCT07598864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a two-drug combination (dapagliflozin plus finerenone) against dapagliflozin alone in 88 adults with type 2 diabetes and chronic kidney disease. The goal is to see if the combo better reduces protein in urine, a key sign of kidney damage. Participants take pills daily for 8 weeks, and researchers monitor kidney function and safety. This is a Phase 3 trial, but it is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chittagong medical College hospital
Chittagong, 4203, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a milk protein shield kidneys from diabetes damage?
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?